{"id":708,"date":"2014-08-09T18:25:56","date_gmt":"2014-08-09T22:25:56","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=708"},"modified":"2014-08-31T16:07:44","modified_gmt":"2014-08-31T20:07:44","slug":"did-you-know-that","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2014\/08\/09\/708\/did-you-know-that\/","title":{"rendered":"Did you know that\u2026"},"content":{"rendered":"<ul>\n<li>A Phase 1 study evaluating tigecycline (Tygacil\u00ae) to treat refractory Acute Myeloid Leukemia is currently underway? [1]<a href=\"https:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-712\" src=\"https:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/jpg\" alt=\"\" width=\"267\" height=\"189\" \/><\/a><\/li>\n<li>Niacin extended release tablets (nicotinic acid, Niaspan\u00ae) was associated with a significantly higher rate of infections (appendicitis, bronchitis, cellulitis) compared to placebo in the AIM-HIGH trial which enrolled over 3400 patients? [2]<\/li>\n<li>Macrolides and aminoglycosides have been found to restore gene function by suppressing stop codons? [3,4]<\/li>\n<li>Sirolimus \/ rapamycin (Rapamune\u00ae), an immunosuppressive mTORC1 inhibitor, also has antifungal properties? [5]<\/li>\n<li>Calcineurin inhibitors (cyclosporine- derivatives or cyclophilin-binders like DEB-025) have anti-viral activity against HCV and HIV? [6]<\/li>\n<li>The CARDS toxin of Mycoplasma pneumoniae, a recently discovered virulence factor which causes pulmonary inflammation, and\/or anti-CARDS antibodies were detected in approx. 40% of ventilated ICU patients? [7]<\/li>\n<\/ul>\n<hr \/>\n<p><strong>Abbreviations<\/strong><\/p>\n<p>mTORC1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 mammalian target of rapamycin complex 1<br \/>\nCARDS \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0community-acquired respiratory distress syndrome<\/p>\n<p><strong>References:<\/strong><\/p>\n<p>[1] http:\/\/clinicaltrials.gov\/show\/NCT01332786<br \/>\n[2] http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMc1311039?query=featured_home<br \/>\n[3] Mandell Chapter on Aminoglycosides<br \/>\n[4] Zilverberg.\u00a0 Gut. 2010 Apr;59(4):496-507<br \/>\n[5] Wong.\u00a0 J. Antibiot. 1998; 5: 487<br \/>\n[6] Watt. \u00a0Am J Transplantation, 9:\u00a01707<br \/>\n[7] M Muir.\u00a0 CHEST 139: 305, 2011<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Phase 1 study evaluating tigecycline (Tygacil\u00ae) to treat refractory Acute Myeloid Leukemia is currently underway? [1] Niacin extended release tablets (nicotinic acid, Niaspan\u00ae) was associated with a significantly higher rate of infections (appendicitis, bronchitis, cellulitis) compared to placebo in the AIM-HIGH trial which enrolled over 3400 patients? [2] Macrolides <a class=\"more-link\" href=\"https:\/\/allphasepharma.com\/dir\/2014\/08\/09\/708\/did-you-know-that\/\">Continue reading <span class=\"screen-reader-text\">  Did you know that\u2026<\/span><span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[140],"tags":[460,456,176,458,309,447,452,449,448,459,24,49,443,450,223,453,451,454,455,457,444,445,446,43,426],"class_list":["post-708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interesting_facts","tag-acute-myeloid-leukemia","tag-aim-high","tag-aminoglycoside","tag-aml","tag-antifungal","tag-calcineurin-inhibitor","tag-cards","tag-cyclophilin-binder","tag-cyclosporine","tag-deb-025","tag-hcv","tag-hiv","tag-icu","tag-m-pneumonia","tag-macrolide","tag-mtorc1","tag-mycoplasma","tag-niacin","tag-niaspan","tag-nicotinic-acid","tag-rapamune","tag-rapamycin","tag-sirolimus","tag-tigecycline","tag-tygacil"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/jpg","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-bq","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":689,"url":"https:\/\/allphasepharma.com\/dir\/2014\/08\/04\/689\/some-thoughts-about-eravacycline-based-on-the-phase-2-ciai-study\/","url_meta":{"origin":708,"position":0},"title":"Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study","author":"Harald","date":"August 4, 2014","format":false,"excerpt":"Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1]\u00a0 This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/eravacycline-copy.jpg?fit=481%2C212&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":708,"position":1},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":1234,"url":"https:\/\/allphasepharma.com\/dir\/2015\/01\/26\/1234\/why-some-did-not-make-it\/","url_meta":{"origin":708,"position":2},"title":"Why Some Did Not Make It","author":"Harald","date":"January 26, 2015","format":false,"excerpt":"There are numerous reasons why drugs get stuck in development.\u00a0 Certainly, problems with efficacy or problems with safety are main reasons but there are many other \u2018derailers\u2019 as well.\u00a0 For instance regulatory issues or manufacturing, difficulties can stop a program.\u00a0 Occasionally, a suboptimal dose was chosen because of (1) incomplete\u2026","rel":"","context":"In &quot;Did you know...?&quot;","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"toy train","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/01\/toy-train.jpe","width":350,"height":200},"classes":[]},{"id":2061,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/20\/2061\/polyphor-pol7080-and-the-journey-to-the-land-of-pyocyanea-part-2\/","url_meta":{"origin":708,"position":3},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea\u00a0 (Part 2)","author":"Harald","date":"October 20, 2015","format":false,"excerpt":"Roche\u2019s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in \u201cpatients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment\u201d is enrolling. Well, good luck finding those patients! At best,\u2026","rel":"","context":"In &quot;QIDP Antibiotics&quot;","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea-P2","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P2.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":972,"url":"https:\/\/allphasepharma.com\/dir\/2014\/09\/29\/972\/perusing-the-literature\/","url_meta":{"origin":708,"position":4},"title":"Perusing the Literature","author":"Harald","date":"September 29, 2014","format":false,"excerpt":"Inhibitor\u00a0of the\u00a0NDM\u00a0Enzyme Aspergillomarasmine (AMA) was identified as an inhibitor of the New Delhi metallo-betalactamase (NDM) enzyme. This substance, when combined with meropenem, restored antibiotic activity against an NDM lab strain.\u00a0 \u00a0AMA is a substance which was already tested in the past in humans.\u00a0 Concerns about interference with human metalloenzymes proved\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/NewLit-slider-copy.jpg?fit=640%2C200&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":5569,"url":"https:\/\/allphasepharma.com\/dir\/2025\/10\/16\/5569\/the-antifungal-landscape-1\/","url_meta":{"origin":708,"position":5},"title":"The Antifungal Landscape &#8211; 1","author":"Harald","date":"October 16, 2025","format":false,"excerpt":"Some newer azoles are still in development, but most only target candidiasis.\u00a0 Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever).\u00a0 It has no appreciable activity against candida or aspergillus.\u00a0 Then there is ibrexafungerp, a promising new agent against C. albicans and\u2026","rel":"","context":"In &quot;Recent Literature&quot;","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/antigungals-table.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/antigungals-table.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/antigungals-table.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=708"}],"version-history":[{"count":6,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/708\/revisions"}],"predecessor-version":[{"id":801,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/708\/revisions\/801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/712"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}